Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
Collecting duct carcinoma (CDC) is a rare, extremely aggressive form of renal cancer. Recently, immune checkpoint inhibitors (ICI), anti-programmed death-1 (PD-1) antibody, and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody were approved for use against metastatic renal cell carc...
Saved in:
| Main Authors: | Tetsuya Danno, Shohei Iwata, Fusako Niimi, Sachi Honda, Haruka Okada, Takeshi Azuma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2021/9936330 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01) -
Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
by: Taylor C. Peak, et al.
Published: (2020-01-01) -
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
by: Arun Singh, et al.
Published: (2020-05-01) -
Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Published: (2020-10-01) -
Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
by: Renata Pacholczak-Madej, et al.
Published: (2024-11-01)